|
ACEIs and ARBs (Policy NH9.601), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Acne and Rosacea Agents (Policy NH9.908), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Acterma (Tolicizumab)(Policy NH9.113), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Adakveo (Policy NH9.611), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Age & Quantity Limitation Program Policy (Policy NH9.050), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Anabolic Steroids (Policy NH9.907), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Antidepressants (Policy NH9.502), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Antiemetics (Policy NH9.905), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Antifungal Agents (Policy NH9.406), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Antineoplastic Agents (Policy NH9.700), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Anti-Obesity Medications (NH9.322), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Antipsychotics (Policy NH9.503), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Arcalyst (rilonacept) (Policy NH9.114), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Asthma-Allergy Monoclonal Antibodies (Policy NH9.109), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Benign Prostatic Hyperplasia (BPH) Medications (Policy NH9.805), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Benlysta (Belimumab) (Policy NH9.115), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Beta Blockers (Policy NH9.602), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Bile Acid Sequestrants (Policy NH9.910), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Botox (Policy NH9.209), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Brineura Policy NH9.301), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Buprenorphine and Naloxone Products (Policy NH9.504), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Calcitonin-Gene Related Peptide Antagonist (CGRP) (Policy NH9.205), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Cerdelga (Policy NH9.313), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Cholbam (NH9.308), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Cimzia (Certolizumab pegol) (Policy NH9.116), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Complement Inhibitors (Policy NH9.134), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Cosentyx (Secukinumab) (Policy NH9.117), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Crysvita (Policy NH9.324), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Cuvposa (Glycopyrrolate) (Policy NH9.203), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Cystic Fibrosis Agents (Policy NH9.100), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Daliresp (Policy NH9.111), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Diacomit (Stiripentol) (Policy NH9.201), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Duchenne Muscular Dystrophy Agents Policy (NH9.302), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Dupixent (Dupilumab) (Policy NH9.118), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Egrifta (NH9.304), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Enbrel (etanercept) (Policy NH9.119), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Enhertu (Policy NH9.706), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Entyvio (Policy NH9.120), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Erythropoiesis Stimulating Agents (Policy NH9.609), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Esbriet (Policy NH9.105), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Exforge / Exforge HCT (Policy NH9.623), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Gastrointestinal Agents (Policy NH9.804), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Gattex (Policy NH9.802), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Givlaari (NH9.321), Effective 01/01/2021
|
Pharmacy PA Forms |
|
GnRH Agents (Policy NH9.703), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Growth Hormones (Policy NH9.325), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Hepatitis C (Policy NH9.404), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Hereditary Angioedema (Policy NH9.101), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Homozygous Familial Hypercholesterolemia (Policy NH9.603), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Humira (Policy NH9.121), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Hydroxyprogesterone Caproate (Policy NH9.800), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Ilaris (Policy NH9.122), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Immune Globulin (Policy NH9.110), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Impavido (Miltefosine) (Policy NH9.402), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Inbrija (Policy NH9.213), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Increlex (NH9.317), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Infliximab Products (Policy NH9.123), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Insomnia Agents (Policy NH9.211), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Kanuma (NH9.311), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Kineret (Policy NH9.124), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Korlym (NH9.303), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Krystexxa (Pegloticase) (Policy NH9.108), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Lambert Eaton Myasthenic Syndrome (Policy NH9.135), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Lucemyra (Policy NH9.501), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Mepsevii (NH9.316), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Metabolic Bone Disease Agents (NH9.318), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Methotrexate (Policy NH9.125), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Mozobil (Policy NH9.702), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Multiple Sclerosis (Policy NH9.212), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Myalept (NH9.307), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Mytesi (Policy NH9.903), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Narcolepsy (Policy NH9.208), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Natpara (NH9.309), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Non-Formulary Exceptions (Policy NH9.051), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Non-Preferred Blood Glucose Testing Products (NH9.320), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Non-Preferred PDL Drug Requests (Policy NH9.055), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Nplate (Policy NH9.106), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Nuedexta (Policy NH9.200), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Ocaliva (Obeticholic Acid) (Policy NH9.803), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Ofev (Policy NH9.133), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Olumiant (Policy NH9.132), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Opioids (Policy NH9.210), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Orencia (Policy NH9.126), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Osphena (Policy NH9.300), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Otezla (Policy NH9.127), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Oxbryta (Policy NH9.612), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Padcev (Policy NH9.707), Effective 01/01/2021
|
Pharmacy PA Forms |
|
PCSK9 Inhibitors (Policy NH9.605), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Pegfilgrastim Agents (Policy NH9.622), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Pregabalin and Lyrica (Policy NH9.206), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Prestalia (Policy NH9.614), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Promacta (Policy NH9.107), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Pulmonary Hypertension (Policy NH9.600), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Pyrimethamine (Daraprim) (Policy NH9.400), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Rayaldee (NH9.314), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Reblozyl (Policy NH9.613), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Restaisis, Xiidra (Policy NH9.902), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Rho Kinase Inhibitors (Policy NH9.912), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Rinvoq (Policy NH9.102), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Rituximab (Policy NH9.704), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Samsca (NH9.319), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Savella (Policy NH9.202), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Signifor (NH9.306), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Simponi (Policy NH9.128), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Skyrizi (Policy NH9.140), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Spinal Muscular Atrophy (NH9.315), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Stelara (Policy NH9.129), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Step-Therapy Exceptions (Policy NH9.052), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Strensiq (NH9.312), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Sublingual Immunotherapy (SLIT) Medications (Policy NH9.104), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Synagis (Policy NH9.405), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Systemic Antibiotics (Policy NH9.403), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Taltz (Policy NH9.130), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Tarka (Policy NH9.624), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Tavalisse (Policy NH9.136), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Tepezza (Policy NH9.705), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Topical Immunomodulators (Policy NH9.103), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Topical Medications (MISC) (Policy NH9.906), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Tranexamic Acid (Policy NH9.801), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Trientine (Syprine) (NH9.310), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Viscosupplements (Policy NH9.909), Effective 01/01/2021
|
Pharmacy PA Forms |
|
VMAT 2 Inhibitors (Policy NH9.204), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Vyndaqel, Vyndamax (Policy NH9.323), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Xeljanz (Policy NH9.131), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Xermelo (Policy NH9.701), Effective 01/01/2021
|
Pharmacy PA Forms |
|
Xiaflex (Policy NH9.911), Effective 01/01/2021
|
Pharmacy PA Forms |